Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Aclaris Therapeutics Inc’s stock clocked out at $1.42, down -3.40% from its previous closing price of $1.47. In other words, the price has decreased by -$3.40 from its previous closing price. On the day, 0.96 million shares were traded. ACRS stock price reached its highest trading level at $1.47 during the session, while it also had its lowest trading level at $1.385.
Ratios:
To gain a deeper understanding of ACRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on May 28, 2025, initiated with a Outperform rating and assigned the stock a target price of $8.
H.C. Wainwright Upgraded its Neutral to Buy on December 23, 2024, while the target price for the stock was maintained at $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Leonard Braden Michael bought 206,025 shares of ACRS for $256,357 on Aug 05 ’24. The 10% Owner now owns 14,250,000 shares after completing the transaction at $1.24 per share. On Aug 02 ’24, another insider, Leonard Braden Michael, who serves as the 10% Owner of the company, bought 167,544 shares for $1.29 each. As a result, the insider paid 216,400 and bolstered with 14,043,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 153759008 and an Enterprise Value of 50929360. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.65 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 2.865 whereas that against EBITDA is -0.943.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.41, which has changed by 0.24561405 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 3.56%, while the 200-Day Moving Average is calculated to be -26.71%.
Shares Statistics:
It appears that ACRS traded 952.40K shares on average per day over the past three months and 1941480 shares per day over the past ten days. A total of 108.27M shares are outstanding, with a floating share count of 92.25M. Insiders hold about 14.81% of the company’s shares, while institutions hold 75.05% stake in the company. Shares short for ACRS as of 1749772800 were 4843301 with a Short Ratio of 5.09, compared to 1747267200 on 4568208. Therefore, it implies a Short% of Shares Outstanding of 4843301 and a Short% of Float of 5.33.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
